Afficher la notice abrégée

dc.contributor.authorCuadrado-Castano, Sara
dc.contributor.authorAyllón Barasoain, Juan 
dc.contributor.authorMansour, Mena
dc.contributor.authorIglesia-Vicente, Janis de la
dc.contributor.authorJordan, Stefan
dc.contributor.authorTripathi, Shashank
dc.contributor.authorGarcía Sastre, Adolfo
dc.contributor.authorVillar, Enrique
dc.date.accessioned2024-09-04T10:40:27Z
dc.date.available2024-09-04T10:40:27Z
dc.date.issued2015-05
dc.identifier.issn1535-7163
dc.identifier.urihttp://hdl.handle.net/10259/9526
dc.description.abstractNewcastle disease virus (NDV) is considered a promising agent for cancer therapy due to its oncolytic properties. These include preferential replication in transformed cells, induction of innate and adaptive immune responses within tumors, and cytopathic effects in infected tumor cells due to the activation of apoptosis. To enhance the latter and thus possibly enhance the overall oncolytic activity of NDV, we generated a recombinant NDV encoding the human TNF receptor Fas (rNDV-B1/Fas). rNDV-B1/Fas replicates to similar titers as its wild-type (rNDV-B1) counterpart; however, overexpression of Fas in infected cells leads to higher levels of cytotoxicity correlated with faster and increased apoptosis responses, in which both the intrinsic and extrinsic pathways are activated earlier. Furthermore, in vivo studies in syngeneic murine melanoma models show an enhancement of the oncolytic properties of rNDV-B1/Fas, with major improvements in survival and tumor remission. Altogether, our data suggest that upregulation of the proapoptotic function of NDV is a viable approach to enhance its antitumor properties and adds to the currently known, rationally based strategies to design optimized therapeutic viral vectors for the treatment of cancer.en
dc.description.sponsorshipR01AI088770 from NIAID to A. García-Sastre and PI08/1813 from the Spanish Fondo de Investigaciones Sanitarias (co-financed by FEDER funds from the EU) to E.Villar. S.Cuadrado-Castano was a predoctoral fellowship holder from the Spanish JCYL (co-financed by European Social Funds (EDU/330/2008; 2008–2012). M. Mansour was supported by NCI 5 T32 CA 78207-13 training grant.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherAmerican Association for Cancer Researchen
dc.relation.ispartofMolecular Cancer Therapeutics. 2015, V. 14, n. 5, p. 1247–1258es
dc.subjectFasen
dc.subjectApoptosisen
dc.subjectOncolyticen
dc.subjectVirotherapyen
dc.subjectRecombinant virusen
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.subject.otherSaludes
dc.subject.otherHealthen
dc.subject.otherMicrobiologíaes
dc.subject.otherMicrobiologyen
dc.titleEnhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Modelsen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.1158/1535-7163.MCT-14-0913es
dc.identifier.doi10.1158/1535-7163.MCT-14-0913
dc.relation.projectIDinfo:eu-repo/grantAgreement/NIAID//R01AI088770/US/es
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Fondo de Investigación Sanitaria/PI08%2F1813/ES/es
dc.relation.projectIDinfo:eu-repo/grantAgreement/NCI//5 T32 CA 78207-13/US/es
dc.identifier.essn1538-8514
dc.journal.titleMolecular Cancer Therapeuticsen
dc.volume.number14es
dc.issue.number5es
dc.page.initial1247es
dc.page.final1258es
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersiones


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée